Unicycive Therapeutics, Inc.
UNCY
$6.93
-$0.19-2.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.20% | 36.56% | 105.80% | 143.23% | 91.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.00% | 17.45% | -5.92% | -13.21% | 46.70% |
| Operating Income | 22.00% | -17.45% | 5.92% | 13.21% | -46.70% |
| Income Before Tax | 31.86% | -46.75% | -165.42% | 102.72% | -176.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.86% | -46.75% | -165.42% | 102.72% | -176.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.86% | -46.75% | -165.42% | 102.72% | -176.03% |
| EBIT | 22.00% | -17.45% | 5.92% | 13.21% | -46.70% |
| EBITDA | 22.04% | -17.41% | 6.00% | 13.21% | -46.66% |
| EPS Basic | 66.39% | 27.75% | -113.34% | 100.56% | 8.99% |
| Normalized Basic EPS | 66.38% | 27.73% | -120.16% | 100.81% | 8.99% |
| EPS Diluted | 66.39% | 27.75% | 64.20% | 93.54% | 8.99% |
| Normalized Diluted EPS | 66.38% | 27.73% | -150.01% | 100.77% | 8.99% |
| Average Basic Shares Outstanding | 102.72% | 103.11% | 224.47% | 234.91% | 203.29% |
| Average Diluted Shares Outstanding | 102.72% | 103.11% | 30.80% | 255.02% | 203.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |